Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3- Octreotide: Preliminary report in cancer patients

G. Paganelli, S. Zoboli, M. Cremonesi, H. R. Mäcke, M. Chinol

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Recent advances in receptor mediated tumor imaging led to the development of a new somatostatin analogue DOTA-D-Phe1-Tyr3-Octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, stable labeling with yttrium-90 (90Y) and favourable biodistribution in patients. The aim of this work was to evaluate acute and late toxicity and the response rate in cancer patients administered 90YDOTATOC. Twenty patients received three equal i.v. injections of 90Y- DOTATOC. Cohorts of 5 patients were treated starting with 1.1 GBq per cycle in escalating dosage (0.4 GBq increments) in subsequent groups. No patients showed acute or delayed major adverse reactions up to the dose of 22 GBq of 90Y-DOTATOC per cycle (6.6 GBq total). Maximum tolerated dose has not been determined yet. One patient, after 4.4 GBq total dose, developed delayed kidney grade II toxicity. Complete and partial tumor mass reduction (CR and PR) was measured in 25% of patients along with 55% showing stable disease (SD) and 20% progressive disease (PD). These results indicate that high activities of 90Y-DOTATOC can be administered with low risk of myelotoxicity, although the radiation doses to the kidneys require careful consideration. Tumor doses were high enough in most cases to obtain objective therapeutic responses.

Original languageEnglish
Pages (from-to)477-483
Number of pages7
JournalCancer Biotherapy and Radiopharmaceuticals
Volume14
Issue number6
Publication statusPublished - 1999

Fingerprint

Octreotide
Radioisotopes
Neoplasms
Therapeutics
Kidney
Yttrium
Somatostatin Receptors
Maximum Tolerated Dose
Somatostatin
Radiation
Injections
DOTA-Tyr(3)-90Y-octreotide

Keywords

  • Y/In- DOTATOC
  • Peptide-receptor radiotherapy
  • Somatostatin analogue

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

@article{fe7770e2e951414b84f199906f2002b1,
title = "Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3- Octreotide: Preliminary report in cancer patients",
abstract = "Recent advances in receptor mediated tumor imaging led to the development of a new somatostatin analogue DOTA-D-Phe1-Tyr3-Octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, stable labeling with yttrium-90 (90Y) and favourable biodistribution in patients. The aim of this work was to evaluate acute and late toxicity and the response rate in cancer patients administered 90YDOTATOC. Twenty patients received three equal i.v. injections of 90Y- DOTATOC. Cohorts of 5 patients were treated starting with 1.1 GBq per cycle in escalating dosage (0.4 GBq increments) in subsequent groups. No patients showed acute or delayed major adverse reactions up to the dose of 22 GBq of 90Y-DOTATOC per cycle (6.6 GBq total). Maximum tolerated dose has not been determined yet. One patient, after 4.4 GBq total dose, developed delayed kidney grade II toxicity. Complete and partial tumor mass reduction (CR and PR) was measured in 25{\%} of patients along with 55{\%} showing stable disease (SD) and 20{\%} progressive disease (PD). These results indicate that high activities of 90Y-DOTATOC can be administered with low risk of myelotoxicity, although the radiation doses to the kidneys require careful consideration. Tumor doses were high enough in most cases to obtain objective therapeutic responses.",
keywords = "Y/In- DOTATOC, Peptide-receptor radiotherapy, Somatostatin analogue",
author = "G. Paganelli and S. Zoboli and M. Cremonesi and M{\"a}cke, {H. R.} and M. Chinol",
year = "1999",
language = "English",
volume = "14",
pages = "477--483",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3- Octreotide

T2 - Preliminary report in cancer patients

AU - Paganelli, G.

AU - Zoboli, S.

AU - Cremonesi, M.

AU - Mäcke, H. R.

AU - Chinol, M.

PY - 1999

Y1 - 1999

N2 - Recent advances in receptor mediated tumor imaging led to the development of a new somatostatin analogue DOTA-D-Phe1-Tyr3-Octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, stable labeling with yttrium-90 (90Y) and favourable biodistribution in patients. The aim of this work was to evaluate acute and late toxicity and the response rate in cancer patients administered 90YDOTATOC. Twenty patients received three equal i.v. injections of 90Y- DOTATOC. Cohorts of 5 patients were treated starting with 1.1 GBq per cycle in escalating dosage (0.4 GBq increments) in subsequent groups. No patients showed acute or delayed major adverse reactions up to the dose of 22 GBq of 90Y-DOTATOC per cycle (6.6 GBq total). Maximum tolerated dose has not been determined yet. One patient, after 4.4 GBq total dose, developed delayed kidney grade II toxicity. Complete and partial tumor mass reduction (CR and PR) was measured in 25% of patients along with 55% showing stable disease (SD) and 20% progressive disease (PD). These results indicate that high activities of 90Y-DOTATOC can be administered with low risk of myelotoxicity, although the radiation doses to the kidneys require careful consideration. Tumor doses were high enough in most cases to obtain objective therapeutic responses.

AB - Recent advances in receptor mediated tumor imaging led to the development of a new somatostatin analogue DOTA-D-Phe1-Tyr3-Octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, stable labeling with yttrium-90 (90Y) and favourable biodistribution in patients. The aim of this work was to evaluate acute and late toxicity and the response rate in cancer patients administered 90YDOTATOC. Twenty patients received three equal i.v. injections of 90Y- DOTATOC. Cohorts of 5 patients were treated starting with 1.1 GBq per cycle in escalating dosage (0.4 GBq increments) in subsequent groups. No patients showed acute or delayed major adverse reactions up to the dose of 22 GBq of 90Y-DOTATOC per cycle (6.6 GBq total). Maximum tolerated dose has not been determined yet. One patient, after 4.4 GBq total dose, developed delayed kidney grade II toxicity. Complete and partial tumor mass reduction (CR and PR) was measured in 25% of patients along with 55% showing stable disease (SD) and 20% progressive disease (PD). These results indicate that high activities of 90Y-DOTATOC can be administered with low risk of myelotoxicity, although the radiation doses to the kidneys require careful consideration. Tumor doses were high enough in most cases to obtain objective therapeutic responses.

KW - Y/In- DOTATOC

KW - Peptide-receptor radiotherapy

KW - Somatostatin analogue

UR - http://www.scopus.com/inward/record.url?scp=0033396445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033396445&partnerID=8YFLogxK

M3 - Article

C2 - 10850334

AN - SCOPUS:0033396445

VL - 14

SP - 477

EP - 483

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 6

ER -